Provide Robust Patient Access Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– Approval Based on Results from ACTIVATE and ACTIVATE-T Phase 3 Studies, Supports Treatment of Adults with PK Deficiency Regardless of Transfusion Status.

United statesUnited kingdomKim hallJackie fouseCompany to provide robust patient access programsCancer centerEuropean hematology associationDrug administrationHarvard medical schoolPatient assistance programAmerican society of hematologyEuropean medicines agencyAgios pharmaceuticals incVirtual congressApproval basedSupports treatment